Perspective on BRCA1

Breast Disease

Volumn 10, Issue 1-2, 1998, Pages 3-10

  Newman, Beth ^a   Liu, Edison T ^b  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMA PROTEIN;

BREAST CANCER; CANCER SUSCEPTIBILITY; CHROMOSOME 13Q; CHROMOSOME 17Q; GENE LOCATION; GENE MAPPING; GENETIC MARKER; GENOTYPE; MOLECULAR CLONING; MOLECULAR GENETICS; PHENOTYPE; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; REVIEW;

EID: 0031966174     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: 10.3233/BD-1998-101-203     Document Type: Review

References (61)

1. Bailey-Wilson J, Cannon LA, King M-C. Genetic analysis of human breast cancer: A synthesis of contributions to GAW IV. Genet Epidemiol 1986; suppl 1:15-35.
2. Hall J, Lee M, Newman B, et al. Linkage of early onset familial breast cancer to chromosome 17q21. Science 1990; 250:1684-1689.
3. Miki Y, Swenson J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266:66-71.
4. Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994; 265:2088-2090.
5. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378:789-792.
6. Khoury MJ, Beaty TH, Liang K-Y. Can familial aggregation of disease be explained by familial aggregation of environmental risk factors? Am J Epidemiol 1988; 127:674-683.
7. Hopper JL, Carlin JB. Familial aggregation of a disease consequent upon correlation between relatives in a risk factor measured on a continuous scale. Am J Epidemiol 1992; 136:1138-1147.
8. Peto J. Genetic predisposition to cancer. In: Cairns J, Lyon JL, Skolnick M, eds. Cancer incidence in defined populations (Banbury Report no. 4). Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1980; 203-213.
9. Weiss KM, Chakraborty R, Majumder PP. Problems in the assessment of relative risk of chronic disease among biological relatives of affected individuals. J Chron Dis 1982; 35:539-551.
10. Eby N, Chang-Claude J, Bishop DT. Familial risk and genetic susceptibility for breast cancer. Cancer Causes Control 1994; 5:458-470.
11. Newman B, Millikan RC, King M-C. Genetic epidemiology of breast and ovarian cancers. Epidemiol Rev 1997; 19:69-79.
12. Bowcock AM, Hall JM, Hebert JM, King M-C. Exclusion of the Retinoblastoma gene and chromosome 13q as the site of a primary lesion for human breast cancer. Am J Hum Genet 1990; 46:12-17.
13. Margaritte P, Bonaiti-Pellie C, King M-C, Clerget-Darpoux F. Linkage of familial breast cancer to chromosome 17q21 may not be restricted to early-onset disease. Am J Hum Genet 1992; 50:1231-1234.
14. Hall JM, Zuppan PJ, Anderson LA, et al. Oncogenes and human breast cancer. Am J Hum Genet 1989; 44:577-584.
15. Krontiris TG, Devlin B, Karp DD, et al. An association between the risk of cancer and mutations in the HRAS1 minisatellite locus. N Engl J Med 1993; 329:517-523.
16. Garrett PA, Hulka BS, Kim YL, Farber RA. HRAS protooncogene polymorphism and breast cancer. Cancer Epidemiol Biomark Prev 1993; 2:131-138.
17. Conway K, Edmiston SN, Hulka BS, Garrett PA, Liu ET. Internal sequence variations in the Haras variable number tandem repeat rare and common alleles by minisatellite variant repeat polymerase chain reaction. Cancer Res 1996; 56:4773-4777.
18. Krontiris TG. Minisatellites and human disease. Science 1995; 269:1682-1683.
19. Spielman RS, Mcginnis RE, Ewens WJ. Transmission test for linkage disequilibrium: The insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am J Hum Genet 1993; 52:506-516.
20. Spielman RS, Ewens WJ. The TDT and other family-based tests for linkage disequilibrium and association. Am J Hum Genet 1996; 59:983-989.
21. Zuppan P, Hall JM, Lee MK, et al. Possible linkage of the estrogen receptor gene to breast cancer in a family with late-onset disease. Am J Hum Genet 1991; 48:1065-1068.
22. Andersen T, Heimdal K, Skrede M, et al. Oestrogen receptor polymorphisms and breast cancer susceptibility. Hum Genet 1994; 94:665-670.
23. Struewing JP, Abeliovich D, Peretz T, et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 1995; 11:198-200.
24. Levy-Lahad E, Catane R, Eisenberg S, et al. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: Frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet 1997; 60:1059-1067.
25. Berman DB, Wagner-Costalas J, Schultz DC, et al. Two distinct origins of a common BRCA1 mutation in breast-ovarian cancer families: A genetic study of 15 185delAG-mutation families. Am J Hum Genet 1996; 58:1166-1176.
26. Gudmundsson J, Johannesdottir G, Arason A, et al. Frequent occurrence of BRCA2 linkage in Icelandic breast cancer families and segregation of a common BRCA2 haplotype. Am J Hum Genet 1996; 58:749-756.
27. Johannesdottir G, Gudmundsson J, Bergthorsson JT, et al. High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients. Cancer Res 1996; 56:3663-3665.
28. Thorlacius S, Olafsdottir G, Tryggvadottir L, et al. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 1996; 13:117-119.
29. Shattuck-Eidens D, McClure M, Simard J, et al. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. JAMA 1995; 273:535-541.
30. Breast Cancer Information Core (BIC). http://www.nhgri.nih.gov/Intramural_research/Lab-transfer/Bic/index.html.
31. Schubert E, Lee M, Mefford H, et al. BRCA2 in American families with four or more cases of breast or ovarian cancer: Recurrent and novel mutations, variable expression, penetrance, and characteristics of families not attributable to BRCA1 or BRCA2. Am J Hum Genet 1997; 60:1031-1040.
32. Rebbeck TR, Couch FJ, Kant J, et al. Genetic heterogeneity in hereditary breast cancer: Role of BRCA1 and BRCA2. Am J Hum Genet 1996; 59:547-553.
33. Narod S, Ford D, Devilee P, et al. Genetic heterogeneity of breast-ovarian cancer revisited. Am J Hum Genet 1995; 57:957-958.
34. Easton DF, Bishop DT, Ford D, et al. Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families. Am J Hum Genet 1993; 52:678-701.
35. FitzGerald MG, MacDonald DJ, Krainer M, et al. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 1996; 334:143-149.
36. Krainer M, Silva-Arrieta S, FitzGerald MG, et al. Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. N Engl J Med 1997; 336:1416-1421.
37. Couch FJ, DeShano ML, Blackwood A, et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 1997; 336:1409-1415.
38. Shattuck-Eidens D, Oliphant A, McClure M, et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations: Risk factor analysis and implications for genetic testing. JAMA 1997; 278:1242-1250.
39. Langston AA, Malone KE, Thompson JD, et al. BRCA1 mutations in a population-based sample of young women with breast cancer. N Engl J Med 1996; 334:137-142.
40. Newman B, Mu H, Butler LM, et al. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 1998; 279:915-921.
41. Offitt K, Gilewski T, McGuire P, et al. Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet 1996; 347:1643-1645.
42. Muto MG, Cramer DW, Tangir J, et al. Frequency of the BRCA1 185delAG mutation among Jewish women with ovarian cancer and matched population controls. Cancer Res 1996; 56:1250-1252.
43. Ford D, Easton DF, Bishop DT, et al. Risks of cancer in BRCA1-mutation carriers. Lancet 1994; 343:692-695.
44. Easton DF, Ford D, Bishop DT, et al. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet 1995; 56:265-271.
45. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336:1401-1408.
46. Holt JT, Thompson ME, Szabo C, et al. Growth retardation and tumor inhibition by BRCA1. Nat Genet 1996; 12:298-302.
47. Thompson ME, Jensen RA, Obermiller PS, Page, DL, Holt JT. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 1995; 9:444-450.
48. Humphery JS, Salim A, Erdos MR, Collins FS, Brody LC, Klausner RD. Human BRCA1 inhibits growth in yeast: Potential use in diagnostic testing. Proc Natl Acad Sci USA 1997; 94:5820-5825.
49. Chen Y, Chen CF, Riley DJ, et al. Aberrant subcellular localization of BRCA1 in breast cancer. Science 1995; 270:789-791.
50. Futreal PA, Liu Z, Shattuck-Eidens D, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994; 266:120-122.
51. Merajver SD, Pham TM, Caduff RF, et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumors. Nat Genet 1995; 9439-9443.
52. Jones K, Brown M, Solomon E. Molecular genetics of sporadic and familial breast cancer. Cancer Surv 1995; 25:315-334.
53. Gudas JM, Li T, Nguyen H, Jensen D, Rauscher FJ III, Cowan KH. Cell cycle regulation of BRCA1 messenger RNA in human breast epithelial cells. Cell Growth Differ 1996; 7:717-723.
54. Hakem R, de la Pompa JL, Sirard C, et al. The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell 1990; 85:1009-1023
55. Monteiro ANA, Aungust A, Hanafusa H. Evidence for a transcriptional activation function of BRCA1 C-terminal region. Proc Natl Acad Sci USA 1996; 93:13595-13599.
56. Chapman MS, Verma IM. Transcriptional activation by BRCA1. Nature (London) 1996; 382:678-679.
57. Scully R, Anderson SF, Chao DM, et al. BRCA1 is a component of the RNA polymerase II holoenzyme. Proc Natl Acad Sci USA 1997; 94:5605-5610.
58. Scully R, Chen J, Plug A, et al. Association of BRCA1 with RAD51 in mitotic and meiotic cells. Cell 1997; 88:265-275.
59. Chen CF, Li S, Chen Y, Chen PI, Sharp ZD, Lee WH. The nuclear localization sequences of the BRCA1 protein interact with the importin-alpha subunit of the nuclear transport signal receptor. J Biol Chem 1996; 271:32863-32868.
60. Wu LC, Wang ZW, Tsan JT, et al. Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat Genet 1996; 14:430-440.
61. Scully R, Chen J, Ochs RL, et al. Dynamic changes of BRCA1 subnuclear localization and phosphorylation state are initiated by DNA damage. Cell 1997; 90:425-435.